However, it is likely that future developments will focus on agents that more selectively activate anti-tumor immunity, e.g., by targeting wild-type or mutant IL-2 to tumors or tumor-specific T cells, and that they will consider emerging knowledge of the effects of IL-2 and IL-2 variants on T cell exhaustion/differentiation. This evidence concerns the gene IL2 and neoplasm.